{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:00:37Z","timestamp":1791644437395,"version":"4.3.4"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>FIGO grade 3 endometrioid endometrial carcinoma (EEC) is a heterogenous group of tumors with variable molecular and clinicopathologic characteristics but is treated clinically as a single entity. There is a need for additional objective markers to help guide management. The aim of this study was to evaluate a cohort of FIGO grade 3 EEC to validate the prognostic impact of molecular classification using <jats:italic toggle=\"yes\">POLE<\/jats:italic> mutation (<jats:italic toggle=\"yes\">POLE<\/jats:italic>-mut) analysis and immunohistochemistry for p53 and mismatch repair proteins. A secondary aim was to assess for any morphologic or immunophenotypic correlates among the molecular groups. Ninety-five cases of FIGO grade 3 EEC who underwent a hysterectomy at our institution were identified. Ten tumors (11%) harbored <jats:italic toggle=\"yes\">POLE<\/jats:italic>-mut, 35 tumors (37%) showed mismatch repair deficiency, 18 tumors (19%) showed aberrant p53 staining (p53-ab), and 26 cases (27%) lacked all of these findings and were classified as no specific molecular profile. Six separate cases harbored &gt;1 abnormality (multiple classifier), 5 of which had <jats:italic toggle=\"yes\">POLE<\/jats:italic>-mut. The <jats:italic toggle=\"yes\">POLE-<\/jats:italic>mut group and multiple classifier group showed excellent clinical outcomes, the p53-ab group showed the worst clinical outcomes and the 2 remaining groups showed intermediate prognosis. While the <jats:italic toggle=\"yes\">POLE<\/jats:italic>-mut tumors showed a statistically significant enrichment for morphologic features including serous-like atypia and lymphocytic infiltrates, these findings were seen across all 4 molecular groups. There was no correlation between molecular grouping and tumor immunophenotypic findings, but overall 18% and 24% of tumors were completely negative for PAX-8 and estrogen receptor, respectively. Five <jats:italic toggle=\"yes\">CTNNB1<\/jats:italic> mutations were identified, 3 of which occurred in the context of a <jats:italic toggle=\"yes\">POLE<\/jats:italic>-mut (including 1 multiple classifier case with MLH1\/PMS2 loss). Thus our study corroborates the prognostic impact of molecular classification of high-grade endometrioid carcinoma of the uterus, achieved by readily available immunohistochemical stains in addition to <jats:italic toggle=\"yes\">POLE<\/jats:italic>-mut analysis.<\/jats:p>","DOI":"10.1097\/pas.0000000000001598","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T07:48:40Z","timestamp":1601970520000},"page":"421-429","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":49,"title":["Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features"],"prefix":"10.1097","volume":"45","author":[{"given":"Amy","family":"Joehlin-Price","sequence":"first","affiliation":[{"name":"Department of Pathology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Van Ziffle","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy K.","family":"Hills","sequence":"additional","affiliation":[{"name":"Neurology, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ladwig","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Rabban","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Garg","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.15585\/mmwr.mm6748a1","article-title":"Uterine cancer incidence and mortality\u2014United States, 1999\u20132016","volume":"67","author":"Henley","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/PGP.0000000000000212","article-title":"The genomic heterogeneity of FIGO grade 3 endometrioid carcinoma impacts diagnostic accuracy and reproducibility","volume":"35","author":"Hussein","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2014.05.006","article-title":"POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium","volume":"134","author":"Meng","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R10-20250608","article-title":"Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma","author":"Brett","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","article-title":"Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment","volume":"143","author":"Talhouk","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/PAS.0000000000001395","article-title":"PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups","volume":"44","author":"Pasanen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.06.008","article-title":"Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated endometrial cancers: new candidates for checkpoint blockade immunotherapy?","volume":"48","author":"Gargiulo","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R15-20250608","first-page":"5955","article-title":"Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research","volume":"37","author":"Gadducci","year":"2017","journal-title":"Anticancer Res"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.humpath.2007.05.022","article-title":"Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer","volume":"39","author":"Shia","year":"2008","journal-title":"Hum Pathol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/PAS.0b013e318197a046","article-title":"Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities","volume":"33","author":"Garg","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/modpathol.2014.143","article-title":"Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations","volume":"28","author":"Hussein","year":"2015","journal-title":"Mod Pathol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PAS.0000000000000764","article-title":"Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on The Cancer Genome Atlas (TCGA)-based molecular subgroup","volume":"41","author":"Hoang","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2013.102","article-title":"Reproducibility of histological cell type in high-grade endometrial carcinoma","volume":"26","author":"Han","year":"2013","journal-title":"Mod Pathol"},{"issue":"suppl 1","key":"R21-20250608","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cncr.29046","article-title":"Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing","volume":"121","author":"Billingsley","year":"2015","journal-title":"Cancer"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2016.11.023","article-title":"Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro","volume":"144","author":"Bellone","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2015.12.031","article-title":"Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas","volume":"141","author":"Wong","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1101\/gr.174789.114","article-title":"Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication","volume":"24","author":"Shinbrot","year":"2014","journal-title":"Genome Res"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-15-2233","article-title":"Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis","volume":"22","author":"McConechy","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2019.10.028","article-title":"Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer","volume":"156","author":"Stasenko","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2018.07.020","article-title":"Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial","volume":"151","author":"Wortman","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u201cmultiple classifier\u201d endometrial carcinomas","volume":"250","author":"Leon-Castillo","year":"2019","journal-title":"J Pathol"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"201","DOI":"10.6004\/jnccn.2017.7066","article-title":"Evolving roles of histologic evaluation and molecular\/genomic profiling in the management of endometrial cancer","volume":"16","author":"Murali","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R34-20250608","first-page":"1040","article-title":"A multiplex SNaPshot assay is a rapid and cost-effectivemethod for detecting POLE mutations in endometrial carcinoma (abstract #1086)","volume":"33","author":"Devereaux","year":"2020","journal-title":"Mod Pathol"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PGP.0000000000000583","article-title":"Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma","volume":"39","author":"Costigan","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"dju245","DOI":"10.1093\/jnci\/dju245","article-title":"Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma","volume":"106","author":"Liu","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R38-20250608","first-page":"8","article-title":"Mutation hotspots in the beta-catenin gene: lessons from the Human Cancer Genome Databases","volume":"42","author":"Kim","year":"2019","journal-title":"Mol Cells"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41379-018-0080-0","article-title":"Nuclear beta-catenin localization and mutation of the CTNNB1 gene: a context-dependent association","volume":"31","author":"Kim","year":"2018","journal-title":"Mod Pathol"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/his.13338","article-title":"Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf\u2019s clothing","volume":"72","author":"Van Gool","year":"2018","journal-title":"Histopathology"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PGP.0000000000000248","article-title":"Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers","volume":"35","author":"Ramalingam","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"e6248","DOI":"10.1097\/MD.0000000000006248","article-title":"High expression of SALL4 and fascin, and loss of E-cadherin expression in undifferentiated\/dedifferentiated carcinomas of the endometrium: an immunohistochemical and clinicopathologic study","volume":"96","author":"Onder","year":"2017","journal-title":"Medicine (Baltimore)"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:05:08Z","timestamp":1749420308000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001598","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,5]]}}}